

Minutes of the annual general meeting of Ambu A/S held on 13 December 2023 at 1:00 pm (CET) at the company's address at Baltorpbakken 13, 2750 Ballerup.

The agenda for the general meeting included:

1. Management's review of the company's activities in the past year
2. Presentation of the annual report and the consolidated financial statements for adoption
3. Presentation for adoption of the remuneration report
4. Proposal of the board of directors on the appropriation of profit in accordance with the adopted annual report
5. Approval of the board of directors' remuneration for the financial year 2023/24
6. Election of chair of the board of directors
7. Election of vice chair of the board of directors
8. Election of other members of the board of directors
9. Election of auditor
10. Proposals from the board of directors:
 - 10.1 Renewal of the board of directors' authorisation to increase the B share capital (article 9e of the Articles of Association)
 - 10.2 Indemnification scheme
 - (a) Adoption of indemnification scheme
 - (b) Amendment of the Articles of Association (indemnification scheme)
 - (c) Update of the remuneration policy (indemnification scheme)
11. Authorisation to the chair of the meeting

Jørgen Jensen, chair of the board of directors, welcomed to the annual general meeting and gave the floor to Niels Korerup, lawyer, who had been appointed chair of the meeting by the board of directors in accordance with article 14 of the company's Articles of Association.

The chair of the meeting informed that shareholders following the annual general meeting through webcast accessible at the Investor Portal had the opportunity to submit questions and comments during the annual general meeting.

With consent from the general meeting, the chair of the meeting stated that the general meeting had been legally convened and was legally competent to transact business.

The chair of the meeting stated that an entry control showed that 72.6% of the share capital (after reduction for the company's treasury shares) was represented and that 87.3% of the votes (also after reduction for the company's treasury shares) was represented at the annual general meeting. The chair

of the meeting further stated that the board of directors had received proxies and postal votes corresponding to 28.9% of all votes present and 86.7% of the represented share capital.

The chair of the meeting stated that under section 101(5) of the Danish Companies Act a complete account of the voting procedure must be available for each resolution passed. The general meeting agreed to deviate from section 101(5) of the Danish Companies Act to the effect that the complete account was not being made.

Items 1-4 on the agenda were considered collectively.

Re 1-4:

- 1. Management's review of the company's activities in the past year**
- 2. Presentation of the annual report and the consolidated financial statements for adoption**
- 3. Presentation for adoption of the remuneration report**
- 4. Proposal of the board of directors on the appropriation of profit in accordance with the adopted annual report**

The chair of the board of directors, Jørgen Jensen, presented the board of directors' report for the company's activities in the past year, the remuneration report for the financial year 2022/23 and the proposal for the distribution of profit according to the financial statement.

CEO, Britt Meelby Jensen, presented the annual report and the consolidated financial statements for the financial year 2022/23 and reported on the past year as well as on Ambu's outlook.

The chair of the meeting thanked the management for its report and presentation of the annual report and the remuneration report. The chair of the meeting stated that the annual report had been signed by the board of directors, the executive board and the company's auditor, and that the annual report had been provided with an unqualified audit opinion.

The chair of the meeting then presented the profit available for distribution which implied that the group net profit for the year amounted to DKK 168m. The board of directors proposed that all profits were carried forward.

The chair of the meeting opened the debate and gave the floor to Anders Nørskov from Dansk Aktionærforening.

Anders Nørskov thanked the chair of the board of directors and the CEO for their presentation of the annual report and congratulated on the results for the past financial year.

Anders Nørskov noted that the debt ratio had been reduced to 0.7 percentage and summarized some of the steps taken by Ambu to obtain such a reduction, hereunder cost reductions, stopping development projects with long expected payback periods, initiating the new Zoom In strategy, assembling a new executive management team, selling treasury shares and completing a capital increase.

Anders Nørskov mentioned that Ambu had a history of adjusting earnings forecasts downwards, but noted that it seemed as if the new management team had a more realistic approach to earnings than previous management teams, which Anders Nørskov assessed to have a positive effect on restoring investors' trust in Ambu. Thereafter, Anders Nørskov mentioned that goodwill accounted for approximately one-third of Ambu's assets, which led Anders Nørskov to ask the following question:

- 1) Is the management concerned about the fact that goodwill accounted for approximately one-third of Ambu's assets or does management perceive it as an ordinary balance sheet item that does not require special measures?

Thereafter, Anders Nørskov stated that the share price had probably not found a natural level, as the share price had dropped by 40 percentage points and thereafter increased by another 40 percentage points.

Anders Nørskov then the following question:

- 2) What did the customers and competitors think about the progress of Ambu?

Conclusively, Anders Nørskov wished Ambu, the employees and the management good luck in the coming year.

The chair of the meeting gave the floor to Jørgen Jensen, who would answer the first question, whereafter Britt Meelby Jensen would answer the second question.

Jørgen Jensen thanked Anders Nørskov for his kind words and positive remarks and stated that the management would do its best to increase the shareholder value.

Jørgen Jensen noted that goodwill made up around DKK 1.6bn and was mainly related to the two acquisitions of respectively King Systems Corp. (2013) and Invendo Medical GmbH (2017). Jørgen Jensen explained that on an ongoing basis, Ambu conducted a variety of tests and assessments of

the goodwill, including customary impairment tests and assessments of the value and technology behind the goodwill. Jørgen Jensen noted that tests and assessments had been made at the end of the financial year 2022/23, and that based on the results of these tests and assessments, the management did not have a reason for further reducing the value of the goodwill.

Thereafter, Britt Meelby Jensen took the floor to answer the second question.

Britt Meelby Jensen also thanked Anders Nørskov for his kind words and positive remarks. Britt Meelby Jensen mentioned that customer satisfaction was a top priority for Ambu and that across the organisation, employees were working to better understand the customers' needs. Britt Meelby Jensen noted that overall, Ambu's customers were satisfied, including regarding quality and service.

Britt Meelby Jensen mentioned that there was restricted communication with peers, but that it had been noted by peers that Ambu had a disruptive approach to endoscopes, which had been positively received by the market.

The chair of the meeting then gave the floor to shareholder, Kjeld Beyer.

Kjeld Beyer congratulated the management with the financial results for 2022/23 and the progress. Thereafter, Kjeld Beyer asked the following questions:

- 1) Why had the website of the company become so difficult to navigate, including in relation to the financial results, and would Ambu consider publishing five-year results as well as announcements in Danish?
- 2) Would the management elaborate on the bad performance of Ambu in the period prior to and during the COVID-19 pandemic?
- 3) Would the management reconsider to distribute dividend?

The chair of the meeting gave the floor to Britt Meelby Jensen.

Britt Meelby Jensen thanked for the kind remarks. Britt Meelby Jensen noted that going forward changing the website and publishing five-year results would be considered. Britt Meelby Jensen explained that Ambu had decided to publish announcements in English as this was appropriate considering Ambu's shareholder base.

Thereafter, Britt Meelby Jensen explained that Ambu had invested significantly into the gastroenterology and bronchoscope businesses prior to and during the COVID-19 pandemic, which had been unsuccessful, as the customers had not been ready to adapt to new products and related procedures, even though this had been recommended by authorities. Britt Meelby Jensen mentioned that Ambu had learned from

previous years, where Ambu had not to the full extent understood its customers' needs. Britt Meelby Jensen noted that going forward, Ambu would be more cautious with investments, which would be limited to one niche at a time, and significant investments would be subject to seeing an uptake.

In relation to dividends, Britt Meelby Jensen stated that the company's dividend policy remained important to the management. Britt Meelby Jensen explained that it was too premature in this calendar year to distribute dividend considering that the business was still stabilising, and due to the capital increase in March 2023, which would not coincide with a distribution of dividend a half year later. Britt Meelby Jensen emphasized that Ambu going forward would do its best to distribute dividend.

The chair of the meeting then gave the floor to shareholder, Hugo Andersen.

Hugo Andersen reiterated the kind words and positive remarks given by Anders Nørskov in regard to the financial results and the performance by the management.

Following the CEO's presentation, Hugo Andersen referred to the fact that the potential market for Ambu's endoscopy business segment were 100m annual procedures and of that, 23m annual procedures were relevant and potentially within Ambu's reach. Hugo Andersen then noted that Ambu only accounted for endoscopes relating to 2m annual procedures, which led Hugo Andersen to ask the following questions:

- 1) Would the management elaborate on the spread from 23m annual procedures to 2m annual procedures?
- 2) What were the primary factors to obtain higher growth rates within the next 2-3 years?

The chair of the meeting gave the floor to Britt Meelby Jensen, who would answer the questions.

Britt Meelby Jensen thanked for the relevant questions and kind words. Britt Meelby Jensen recognized that there was a significant spread between the market potential and Ambu's market share. Britt Meelby Jensen noted that Ambu was a disrupter in the market, and that time was a significant factor in a gradual market penetration. Britt Meelby Jensen mentioned that Ambu expected a gradual uptake as customers tried Ambu's products and experienced their potential at first hand.

As primary factors going forward, Britt Meelby Jensen mentioned that it was important to (i) remain close to the customers, (ii) maintain a strong product portfolio, and (iii) ensure that production capacity would not become a barrier to growth. In relation to the latter, Britt Meelby Jensen mentioned that it was possible to significantly increase production at the new production plant in Mexico should the growth accelerate.

The chair of the meeting then gave the floor to shareholder, Søren Anker-Ladefoged.

Søren Anker-Ladefoged commented on Ambu's expected growth rate, which Søren Anker-Ladefoged expected would have been higher, as it was stated in the management report that Ambu's endoscopy products were generally cheaper, cleaner, safer and had a more positive ESG impact than competing multi-use products.

Thereafter, Søren Anker-Ladefoged asked the following questions:

- 1) Was Ambu good enough at selling its products, and what measures would the management take in order to increase sales?
- 2) What would Ambu do to ensure higher growth rates within the anaesthesia and patient monitoring business, which had seen growth rates of 1-2 percentage points?
- 3) What would Ambu do to control its costs?

The chair of the meeting gave the floor to Britt Meelby Jensen, who would answer the questions.

Britt Meelby Jensen thanked for the kind words and questions. In relation to sales, Britt Meelby Jensen stated that the management focused on improving Ambu's sales. The sales strategy was an integral part of Ambu's transformation process, which was included in the multiple-year Zoom In strategy, and in the coming years Ambu would work hard to optimise access to markets and increase sales.

Thereafter, Britt Meelby Jensen acknowledged that the executive management team had focused significantly on the endoscopy business segment within the recent years but noted that the anaesthesia and patient monitoring business segments remained important for Ambu. Britt Meelby Jensen mentioned that Ambu considered various measures to increase growth rates within the anaesthesia and patient monitoring business segments, including a price increase.

Afterwards, Britt Meelby Jensen noted that costs were an important part of the transformation process, and that the CFO appointed as per 1 February 2024, Henrik Skak Bender, would bring experience from similar transformation processes as Ambu's. Conclusively, Britt Meelby Jensen stated costs remained a top priority, and that Ambu was constantly considering potential optimisations and scale-ability.

The chair of the meeting then gave the floor to shareholder, Kurt Birk.

Kurt Birk mentioned that he had been the CEO of Ambu from 1998 to 2008. Kurt Birk congratulated the management with the strong performance and the growth rate of six percentage points. Kurt Birk stated that he assessed that Ambu - subject to election under the agenda items 6 to 8 - had the right board composition.

Thereafter, Kurt Birk elaborated on Ambu's product portfolio and the main business segments: anaesthesia, ECG, masks, patient monitoring and endoscopes.

Conclusively, Kurt Birk encouraged Ambu to focus on the sterile areas of the body, and not to forget the non-endoscope business segments within Ambu, which Kurt Birk stated had a great potential, if Ambu allocated the appropriate resources for development and marketing.

The chair of the meeting gave the floor to Jørgen Jensen, who briefly thanked Kurt Birk for his kind words and interesting perspectives. Jørgen Jensen noted that the non-endoscope business segments remained import for Ambu and that resources had been allocated to these business segments.

As no other shareholder wished to take the floor, the chair of the meeting stated, with the consent of the general meeting,

that the shareholders had taken note of the management's review of the company's activities;

that the shareholders had adopted the annual report and the consolidated financial statements;

that the shareholders had adopted the remuneration report; and

that the shareholders had approved the board of directors' proposal on the distribution of profit.

Re. 5 Approval of the board of directors' remuneration for the financial year 2023/24.

The board of directors proposed that the board of directors' remuneration for the financial year 2023/24 remained unchanged from the previous year as stipulated below:

- Ordinary members of the board of directors received basic remuneration amounting to DKK 350,000
- The chair received three times the basic remuneration (DKK 1,050,000)
- The vice-chair received twice the basic remuneration (DKK 700,000)
- In addition, each member of a board committee received remuneration of DKK 117,000 per committee seat, however, the committee chair received remuneration of DKK 175,000 per committee chair seat

As no one wished to take the floor, the chair of the meeting stated, with the consent of the general meeting, that the remuneration for the board of directors for the current financial year was adopted.

Re. 6 Election of chairman of the board of directors.

The board of directors proposed to re-elect Jørgen Jensen as chair of the board of directors. The chair of the meeting referred to annex 1 to the notice convening the annual general meeting for information on the management level posts held by Jørgen Jensen, cf. s. 120 of the Danish Companies Act.

The chair of the meeting stated that there were no other candidates for the position as chair of the board of directors, and thus that Jørgen Jensen was re-elected for a one-year period.

Re. 7 Election of vice chair of the board of directors

The board of directors proposed to elect Shacey Petrovic as vice chair of the board of directors. The chair of the meeting referred to annex 1 to the notice convening the annual general meeting for information on the management level posts held by Shacey Petrovic, cf. s. 120 of the Danish Companies Act.

The chair of the meeting stated that there were no other candidates for the position as vice chair of the board of directors, and thus Shacey Petrovic was elected for a one-year period.

Re. 8 Election of other members of the board of directors.

The board of directors proposed to re-elect the following members:

- Christian Sagild
- Michael del Prado
- Susanne Larsson
- Simon Hesse Hoffmann

The chair of the meeting noted that Henrik Ehlers Wulff had decided not to run for re-election. Thereafter, the chair of the meeting referred to appendix 1 to the notice convening the annual general meeting for information on the management level posts held by the candidates, cf. s. 120 of the Danish Companies Act.

The chair of the meeting stated that there were no other candidates for the position as member of the board of directors, and thus that Christian Sagild, Michael del Prado, Susanne Larsson and Simon Hesse Hoffmann were re-elected for a one-year period.

Re 9 Election of auditor

The board of directors proposed re-election of EY Godkendt Revisionspartnerselskab.

The chair of the meeting noted that the proposal to re-elect EY Godkendt Revisionspartnerselskab as auditor of the company was in accordance with the recommendation of the audit committee, which was not influenced by any third parties, and which had not been subject to any agreement with a third party limiting the general meeting's election of auditor.

The chair of the meeting stated that there were no other proposals for auditor of the company, and thus that EY Godkendt Revisionspartnerselskab was elected as auditor of the company.

Re 10 Proposal from the board of directors

**Re 10.1 Renewal of the board of director's authorisation to increase the B share capital
(article 9e of the Articles of Association)**

The board of directors proposed to renew the existing authorisation to increase the company's B share capital as set out in article 9e of the Articles of Association, as the existing authorisation had been partly exercised.

Specifically, the board of directors proposed to renew the existing authorisation to increase the B share capital with up to nominally DKK 13,464,719 B shares with and without pre-emption rights until and including 12 December 2028. The proposal implied that article 9e of the Articles of Association would read as follows:

"Until and including 12 December 2028, the Board of Directors shall be authorised to increase the Company's share capital in one or more issues by up to a total nominal amount of DKK 13,464,719 Class B shares. Capital increases must be paid up in full in cash and with pre-emption rights for the Company's existing holders of Class A and Class B shares at a price determined by the board of directors.

Until and including 12 December 2028, the Board of Directors shall be authorised to increase the Company's share capital in one or more issues by up to a total nominal amount of DKK 13,464,719 Class B shares. Capital increases may be paid up in full in cash, assets other than cash (contribution in kind) or through the conversion of debt or a combination thereof. Capital increases shall be effected at a price to be determined by the Board of Directors, always provided, however, that the price may not be lower than the market price on the date of the resolution, and without the existing holders of Class A and Class B shares having any pre-emption rights.

The authorisations set out in the first and second paragraph of this article 9e are, however, in the aggregate subject to a maximum nominal amount of DKK 13,464,719 Class B shares.

Moreover, the new Class B shares shall be subject to the same rules as the existing Class B shares of the Company. The shares shall be issued in the name of the holder, recorded in the name of the

holder in the Company's Register of Shareholders and shall be negotiable instruments. The shares shall be subject to the same rules on pre-emption rights, voting rights and redeemability as the existing Class B shares. The new Class B shares shall confer on the shareholder a right to receive dividends and other rights and privileges in the Company as from the date of registration with the Danish Business Authority."

The chair of the meeting stated that adoption of the proposal required approval by at least 2/3 of both the votes cast as well as the voting share capital represented at the general meeting.

With consent from the general meeting, the chair of the meeting stated that the proposal was adopted.

Re 10.2(a) Adoption of indemnification scheme

The chair of the meeting had decided that agenda items 10.2(a), 10.2(b) and 10.2(c) would be considered collectively and thus debated collectively given that all three proposals related to indemnification of members of the Board of Directors.

The Board of Directors proposed that the general meeting adopted an updated indemnification scheme for the members of the Board of Directors. The chair of the meeting referred to the notice convening the general meeting, which explained out that in April 2023, the Danish Business Authority had issued a guiding statement on indemnification of members of the board of directors in Danish limited liability companies, which had caused Ambu to review its existing indemnification scheme to enhance transparency regarding its indemnification scheme. The chair of the meeting stated that the Board of Directors had assessed that the indemnification was in the best interest of Ambu. The chair of the meeting then referred to the notice convening the annual general meeting, which set out the below terms and conditions applicable to the updated indemnification scheme:

Basis and purpose - *Whereas it is the company's policy to take out appropriate and customary directors' and officers' liability insurance for Board Members, experience shows that it is necessary to offer additional coverage for potential management liability in order to attract and retain qualified board members, particularly individuals accustomed to common law liability regimes, in consideration of the business and the risks associated with the position as member of the Board of Directors of Ambu. Furthermore, the company's operations comprise certain activities, which may imply special responsibilities and increased risk exposure for the Board Members, particularly in certain foreign jurisdictions. Accordingly, it is considered in the best interest of Ambu and its shareholders that Board Members are offered indemnification against claims raised by third parties supplemental to the company's D&O Liability Insurance as further outlined below.*

It has been duly considered if the Scheme would imply adverse effects for the company and its shareholders, including if the Scheme would result in excessive and/or hazardous risk-taking behaviour by the Board Members and/or if the Scheme would be redundant if Ambu increased the coverage under the D&O Liability Insurance. Ambu has assessed that such alternative increase of the D&O Liability Insurance coverage would not be commercially viable, and thus not in the interest of the company and its shareholders. Furthermore, the Scheme is deemed not to encourage Board Members to act differently than if the D&O Liability Insurance coverage would be increased.

Covered individuals - *The Scheme shall be for the sole benefit of the Board Members and provide indemnification against claims raised by third parties against the Board Members in the discharge of their duties. No third party shall be entitled to rely on or derive any benefits from the Scheme or have any recourse against the company on account of the Scheme.*

Scope - *Under the Scheme, Ambu shall indemnify and hold harmless a Board Member, to the fullest extent permitted by applicable law, from and against any losses incurred by such Board Member arising out of any actual or potential claims, including any costs, expenses and potential tax liabilities associated therewith, raised by any third party (other than Ambu group companies) against a Board Member based on such Board Member's discharge of his/her duties as Board Member.*

Indemnification of Board Members under the Scheme is not conditioned on coverage under the D&O Liability Insurance and shall be secondary to coverage under the D&O Liability Insurance, as applicable from time to time, and other indemnification sources, if any, i.e., Ambu shall not provide indemnification under the Scheme before coverage under the D&O Liability Insurance and indemnification available from any other source are exhausted. Accordingly, the Scheme may provide coverage for losses which are not covered wholly or partly under the D&O Liability Insurance, as applicable from time to time. Such secondary coverage does not imply an obligation on Ambu to exhaust any and all opportunities to relieve Board Members from liability and does not prevent Ambu from covering Board Members' legal defence costs related to potential liability based on a Board Member's discharge of his/her duties as Board Member.

Covered conduct - *Under the Scheme, indemnification shall apply to any losses incurred by a Board Member arising out of and/or based on such Board Member's discharge of his/her duties as member of the Board of Directors of Ambu. Excluded from indemnification under the Scheme are any losses relating to liability incurred by a Board Member arising out of such Board Member's fraud, criminal offences, wilful misconduct or, to the extent not indemnifiable under Danish law, gross negligence.*

Term and covered claims - *The Scheme shall apply until amended or revoked by the general meeting of Ambu. Subject to the Scheme's terms and conditions, this Scheme covers claims made against a Board Member arising out of or originates from facts or circumstances prior to the expiry of the term of the Scheme. Claims for indemnification must be notified by a Board Member to Ambu as soon as possible after the Board Member's receipt of the claim and no later than 10 years after the expiry of the Scheme's term.*

Implementation, administration and authority - For the purpose of implementing the Scheme, the Board of Directors shall stipulate the procedural and administrative provisions and other necessary regulations governing the Scheme. In order to eliminate potential conflicts of interests, the Scheme shall be administered by a committee or similar body composed of individuals considered independent from the Board of Directors in respect of the Scheme. Furthermore, indemnification of a Board Member's loss under the Scheme shall always be subject to a legal opinion from a reputable law firm setting out that the claim concerned is covered by the Scheme. Ambu's obligation to indemnify Board Members under the Scheme shall be capped at a market consistent level in due consideration of the activities and risk profile of Ambu. All claims for indemnification, including if the conduct of a Board Member is covered by the Scheme, shall be processed and decided in accordance with Danish law. For the purpose of establishing an indemnification scheme for the Executive Board, the Board of Directors stipulates the terms and conditions applicable to such indemnification scheme.

Re 10.2(b) Amendment of the Articles of Association (indemnification scheme)

The Board of Directors proposed that the general meeting adopted the following wording as a new article 19 in the company's Articles of Association in order to provide transparency in respect of the indemnification scheme proposed under agenda item 10.2(a):

"The Company has established an indemnification scheme for members of the Board of Directors. Under the indemnification scheme, the Company shall indemnify members of the Board of Directors from and against any losses incurred by members of the Board of Directors arising out of any claims raised by any third party (other than Ambu group companies) based on such members of the Board of Directors' discharge of their duties as members of the Board of Directors. Excluded from indemnification under the scheme are any losses relating to liability incurred by a member of the Board of Directors arising out of such member's fraud, criminal offences, wilful misconduct or, to the extent not indemnifiable under Danish law, gross negligence. Indemnification under the scheme shall be secondary to coverage from other sources of indemnification or coverage of liability and is not conditioned on coverage under the directors' and officers' liability insurance, as applicable from time to time. Accordingly, the Company may indemnify for losses which are not covered wholly or partly by the directors' and officers' liability insurance. The Board of Directors stipulates provisions on the implementation and administration of the indemnification scheme."

The proposal implied that the numbering of the subsequent articles of the Articles of Association would be altered accordingly.

Re 10.2(c) Update of the remuneration policy (indemnification scheme)

The Board of Directors proposed that the general meeting approved an updated version of the remuneration policy, which reflected the indemnification scheme applicable to members of the Board of Directors

as proposed under agenda item 10.2(a). The chair of the meeting then referred to the draft updated remuneration policy, which had been accessible at Ambu's website prior to the general meeting.

The chair of the meeting stated that adoption of the proposals under the agenda items 10.2(a) and 10.2(c) required approval by a simple majority of votes, and that adoption of the proposal under agenda item 10.2(b) required approval by at least 2/3 of both the votes cast as well as the voting share capital represented at the general meeting.

With consent from the general meeting, the chair of the meeting stated that the proposals under the agenda items 10.2(a), 10.2(b) and 10.2(c) had been adopted.

Re 11 Authorisation to the chair of the meeting

The board of directors proposed that the general meeting authorised the chair of the meeting with full power of substitution to apply for registration of the resolutions passed and to make any such amendments thereto as may be required or requested by the Danish Business Authority or any other public authority as a condition for such registration or approval, and to regularly make and apply for registration of clarifications of the wording and other clarifications without substantive effect to the company's Articles of Association.


With consent from the general meeting, the chair of the meeting stated that the proposal was adopted.

Any other business

Nobody wished to take the floor.

There being no further items on the agenda, the chair of the meeting thanked the shareholders for an orderly general meeting and resigned his duties as chair of the meeting.

Jørgen Jensen thanked Ambu's employees and the executive management team for their great effort throughout the year, and the colleagues in the board of directors for their valuable input and great collaboration. Jørgen Jensen looked forward to continuing the progress with Ambu. Conclusively, Jørgen Jensen thanked the shareholders for attending the annual general meeting and the chair of the meeting for an orderly conduct hereof, whereafter the annual general meeting was adjourned.

A handwritten signature in blue ink, consisting of stylized, overlapping letters that appear to be 'N.K.' or similar initials.

Niels Kornerup
Chair of the meeting